Can irisin be used in the follow-up of osteoporosis treatment?

Abstract

Aim: This study aims to investigate the possible roles of irisin as a biomarker in the diagnosis and follow-up of osteoporosis.
Methods: A total of 32 postmenopausal osteoporotic and 23 healthy postmenopausal women were received in this study. Bone mineral densitometry (BMD) measurements were done for all patients and control groups. Clinical follow-ups were performed every 3 months. To elicit post-treatment values, at the end of the 12-month follow-up period, all patients underwent BMD and biochemical parameters. Serum irisin concentrations were measured by competitive Enzyme-Linked Immunosorbent Assay (ELISA). The detection range of the used kit was 0.5-30 ng/ml.
Results: T-scores were determined as -3.28±0.6 in the BT group (Before treatment) and -2.49±0.7 in the AT group (After-Treatment), and -0.7±0.4 in the control group (C). Significant differences were observed in T scores between BT and AT (p<0.001), BT and C (p<0.001), and AT and C (p<0.001) statistically. Significant differences were observed between BT and C (p<0.001) and AT and C (p=0.002) statistically. There was no significant difference between BT and AT values (p=0.327) statistically. At the correlation analysis, irisin was positively correlated with T score (p=0.01, r=0.25) and 25-OH-D (p=0.02, r=0.23), and negatively correlated with development of osteoporosis (p=0.02, r=-0.23). According to the ROC analysis, irisin levels of 4.1 ng/ml or less can predict pre-treatment osteoporosis with 65.6% specificity and 60% sensitivity (AUC: 65.8%, p=0.014).
Conclusion: We concluded that irisin was a protective factor against osteoporosis. It may be used as a biomarker in the diagnosis of osteoporosis.

Keywords

• Irisin
• osteoporosis
• zoledronic acid
• biomarker

Irisin osteoporoz tedavisi takibinde kullanılabilir mi?

Öz

Amaç: Bu çalışma, osteoporozun tanı ve takibinde bir biyobelirteç olarak irisinin olası rollerini araştırmayı amaçlamaktadır.
Yöntemler: Bu çalışmaya toplam 32 postmenopozal osteoporotik ve 23 sağlıklı postmenopozal kadın alındı. Tüm hasta ve kontrol gruplarında kemik mineral dansitometri (KMY) ölçümleri yapıldı. Klinik takipler 3 ayda bir yapıldı. Tedavi sonrası değerleri ortaya çıkarmak için 12 aylık takip süresinin sonunda tüm hastalara BMD ve biyokimyasal parametreler uygulandı. Serum irisin konsantrasyonları, rekabetçi Enzyme-Linked Immunosorbent Assay (ELISA) ile ölçüldü. Kullanılan kitin algılama aralığı 0,5-30 ng/ml idi.
Bulgular: T-skorları BT grubunda (Tedavi öncesi) -3,28±0,6, AT grubunda (Tedavi Sonrası) -2,49±0,7 ve kontrol grubunda (C) -0,7±0,4 olarak belirlendi. BT ve AT (p<0,001), BT ve K (p<0,001) ve AT ve K (p<0,001) arasında T skorlarında istatistiksel olarak anlamlı farklılıklar gözlendi. BT ile K (p<0,001) ve AT ile K (p=0,002) arasında istatistiksel olarak anlamlı farklar gözlendi. BT ve AT değerleri arasında istatistiksel olarak anlamlı fark yoktu (p=0,327). Korelasyon analizinde irisin, T skoru (p=0,01, r=0,25) ve 25-OH-D (p=0,02, r=0,23) ile pozitif, osteoporoz gelişimi ile negatif korelasyon gösterdi (p=0,02, r=-0,23). ROC analizine göre, 4,1 ng/ml veya daha düşük irisin seviyeleri, %65,6 özgüllük ve %60 duyarlılıkla tedavi öncesi osteoporozu öngörebilir (EAA: %65,8, p=0,014).
Sonuç: İrisinin osteoporoza karşı koruyucu bir faktör olduğu sonucuna vardık. Osteoporoz tanısında biyobelirteç olarak kullanılabilir.

Anahtar Kelimeler

• Irisin
• osteoporoz
• zoledronik asit
• biyomarker

Kaynakça

1. 1. Kelly DP. Medicine. Irisin, light my fire. Science. 2012;6077;42-3.
2. 2. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-8.
3. 3. Kershaw EE, Flier JS. Adipose tissue is an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
4. 4. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191-200.
5. 5. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014;220:47-59.
6. 6. Morgan EN, Alsharidah AS, Mousa AM, Edrees HM. Irisin Has a Protective Role against Osteoporosis in Ovariectomized Rats. Biomed Res Int. 2021;Apr 26;2021:5570229. 7. Al-Daghri NM, Mohammed AK, Al-Attas OS, Amer OE, Clerici M, Alenad A, et al. SNPs in FNDC5 (irisin) are associated with obesity and modulation of glucose and lipid metabolism in Saudi subjects. Lipids Health Dis. 2016;15:54.
7. 8. Briganti SI, Gaspa G, Tabacco G, Naciu AM, Cesareo R, Manfrini S, et al. Irisin as a regulator of bone and glucose metabolism. Minerva Endocrinol. 2018;43:489-500.
8. 9. Qiao X, Nie Y, Ma Y, Chen Y, Cheng R, Yin W, et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci Rep. 2016;6:18732.

9. 10. Wu LF, Zhu DC, Tang CH, Ge B, Shi J, Wang BH, et al. Association of plasma irisin with bone mineral density in a large Chinese population using an extreme sampling design. Calcif Tissue Int. 2018;103:246-51.
10. 11. Yan J, Liu HJ, Guo WC, Yang J. Low serum concentrations of irisin are associated with increased risk of hip fracture in Chinese older women. Joint Bone Spine. 2018;85:353-58.
11. 12. Palermo A, Strollo R, Maddaloni E, Tuccinardi D, D'Onofrio L, Briganti SI, et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition, or daily physical activity. Clin Endocrinol (Oxf). 2015;82:615-9.
12. 13. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int. 2014;25:1633-42.
13. 14. Colaianni G, Notarnicola A, Sanesi L, Brunetti G, Lippo L, Celi M, et al. Irisin levels correlate with bone mineral density in soccer players. J Biol Regul Homeost Agents. 2017;31(4 suppl 1):21-8.
14. 15. Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci USA. 2015;112:12157-62. 16. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Makras P, Perakakis N, Kountouras J, et al. Irisin in metabolic diseases. Endocrine. 2018;59:260-74.
15. 17. Engin-Üstün Y, Çağlayan EK, Göçmen AY, Polat MF. Postmenopausal osteoporosis is associated with serum chemerin and irisin but not with apolipoprotein M levels. J Menopausal Med. 2016;22:76-9.
16. 18. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Makras P, Perakakis N, Kountouras J, Mantzoros CS. Irisin in metabolic diseases. Endocrine. 2018;59:260-74.
17. 19. Briganti SI, Gaspa G, Tabacco G, Naciu AM, Cesareo R, Manfrini S, Palermo A. Irisin as a regulator of bone and glucose metabolism. Minerva Endocrinol. 2018;43:489-500.
18. 20. Li G, Zhang L, Wang D, AIQudsy L, Jiang JX, Xu H, Shang P. Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. J Cell Biochem. 2019;120:14262-73.
19. 21. Xu L, Shen L, Yu X, Li P, Wang Q, Li C. Effects of irisin on osteoblast apoptosis and osteoporosis in postmenopausal osteoporosis rats through upregulating Nrf2 and inhibiting NLRP3 inflammasome. Exp Ther Med. 2020;19:1084-90.
20. 22. Colaianni G, Sanesi L, Sterling G, Brunetti G, Colucci S, Grano M. Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects. Cells. 2019;8:451.
21. 23. Kang YS, Kim JC, Kim JS, Kim SH. Effects of Swimming Exercise on Serum Irisin and Bone FNDC5 in Rat Models of High-Fat Diet-Induced Osteoporosis. J Sports Sci Med. 2019;18:596-603.